ELAN Logo

Elanco Animal Health Incorporated (ELAN) 

NYSE
Market Cap
$6.34B
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
77 of 776
Rank in Industry
2 of 47

Largest Insider Buys in Sector

ELAN Stock Price History Chart

ELAN Stock Performance

About Elanco Animal Health Incorporated

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, …

Insider Activity of Elanco Animal Health Incorporated

Over the last 12 months, insiders at Elanco Animal Health Incorporated have bought $2.23M and sold $0 worth of Elanco Animal Health Incorporated stock.

On average, over the past 5 years, insiders at Elanco Animal Health Incorporated have bought $2.74M and sold $3.25B worth of stock each year.

Highest buying activity among insiders over the last 12 months: Simmons Jeffrey N (PRESIDENT, CEO AND DIRECTOR) — $2.6M. DOYLE WILLIAM F (director) — $1.5M. HOOVER R DAVID (director) — $1.29M.

The last purchase of 3,500 shares for transaction amount of $51,974 was made by Harrington Michael J (director) on 2024‑08‑22.

List of Insider Buy and Sell Transactions, Elanco Animal Health Incorporated

2024-08-22Purchasedirector
3,500
0.0007%
$14.85$51,974-0.75%
2024-08-12PurchasePRESIDENT, CEO AND DIRECTOR
100,000
0.02%
$13.01$1.3M+10.85%
2024-05-21Purchasedirector
15,000
0.0031%
$16.98$254,700-12.87%
2024-03-08Purchasedirector
3,100
0.0006%
$16.29$50,494-10.33%
2024-03-08Purchasedirector
15,000
0.003%
$16.30$244,500-10.33%
2024-03-06Purchasedirector
20,000
0.0041%
$16.14$322,808-8.10%
2023-03-14Purchasedirector
5,000
0.001%
$9.55$47,750+22.55%
2023-03-13Purchasedirector
5,000
0.001%
$9.46$47,288+23.79%
2023-03-10PurchasePRESIDENT, CEO AND DIRECTOR
15,000
0.0031%
$9.60$143,972+19.75%
2023-03-03Purchasedirector
10,000
0.002%
$11.13$111,300+1.35%
2022-11-11Purchasedirector
7,500
0.0015%
$13.24$99,267-16.80%
2022-09-09Purchase
20,000
0.0041%
$15.18$303,614-21.00%
2022-09-09PurchaseSEE REMARKS
13,400
0.0027%
$14.90$199,660-21.00%
2022-09-09PurchasePRESIDENT, CEO AND DIRECTOR
30,000
0.006%
$14.54$436,146-21.00%
2022-09-09Purchase
20,000
0.0041%
$15.03$300,500-21.00%
2022-05-20Purchase
20,000
0.0039%
$23.33$466,538-46.79%
2022-05-11Purchase
20,000
0.0043%
$22.03$440,568-37.18%
2022-03-02Purchasedirector
10,000
0.002%
$29.00$290,000-46.97%
2022-03-01Purchasedirector
10,000
0.002%
$28.66$286,645-46.86%
2022-03-01Purchasedirector
2,000
0.0004%
$28.48$56,958-46.86%

Insider Historical Profitability

<0.0001%
HOOVER R DAVIDdirector
185000
0.0374%
$12.84230<0.0001%
Simmons Jeffrey NPRESIDENT, CEO AND DIRECTOR
145000
0.0293%
$12.8470<0.0001%
Harrington Michael Jdirector
81094
0.0164%
$12.8460<0.0001%
DOYLE WILLIAM Fdirector
76330
0.0154%
$12.8420
BILBREY JOHN Pdirector
41722
0.0084%
$12.8460<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Dodge & Cox$1.37B16.9783.85M-0.16%-$2.15M0.8
PRIMECAP Management Co$860.97M10.752.89M+4.51%+$37.2M0.63
The Vanguard Group$801.92M9.9749.26M-0.42%-$3.43M0.02
BlackRock$433.7M5.3926.64M-4.12%-$18.62M0.01
T. Rowe Price$360.43M4.4822.14M+4%+$13.88M0.04
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.